Vermont House Bill H0859

Vermont 2025-2026 Regular Session

• Introduced: 2/3/26
• Refer: 2/3/26

Caption

An act relating to psychedelic therapy and clinical drug development trials

Impact

If enacted, H0859 will have a significant impact on state laws regarding the control and use of psychedelics for therapeutic purposes. The creation of the Psychedelic Therapy Advisory Board indicates a legislative intent to formally explore and potentially integrate psychedelic therapies into Vermont's healthcare system. This could lead to expanded treatment options for mental health conditions resistant to traditional therapies, reflecting a progressive shift in state policy concerning the medical use of hallucinogenics.

Summary

House Bill H0859 seeks to establish a Psychedelic Therapy Advisory Board in Vermont, as well as to initiate clinical drug development trials for ibogaine, a compound reputed for its potential therapeutic benefits in treating substance use disorders and mental health conditions. The bill mandates the Department of Health to contract with a Vermont-based entity to conduct these trials, aligning with expanding research that supports the medical use of psychedelics. The goal is to gather clinical evidence that might soon enable practitioners to prescribe psychedelics under state law.

Contention

There is notable contention surrounding H0859. While proponents argue that ibogaine presents a breakthrough opportunity in combatting opioid use disorder and related mental health issues, critics may raise concerns about the safety and efficacy of psychedelics in medical contexts. Furthermore, ethical considerations regarding the accessibility and regulation of such therapies could spark debates among various stakeholders, including healthcare professionals, lawmakers, and the public.